Connection

THOMAS A BUCHHOLZ to Lymphatic Metastasis

This is a "connection" page, showing publications THOMAS A BUCHHOLZ has written about Lymphatic Metastasis.
Connection Strength

2.717
  1. The value of ultrasound in detecting extra-axillary regional node involvement in patients with advanced breast cancer. Oncologist. 2012; 17(11):1402-8.
    View in: PubMed
    Score: 0.223
  2. Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol. 2011 Dec 01; 29(34):4479-81.
    View in: PubMed
    Score: 0.210
  3. Internal mammary node radiation: a proposed technique to spare cardiac toxicity. J Clin Oncol. 2009 Nov 01; 27(31):e172-3; author reply e174.
    View in: PubMed
    Score: 0.178
  4. Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1074-9.
    View in: PubMed
    Score: 0.126
  5. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2002 Jul 15; 53(4):880-8.
    View in: PubMed
    Score: 0.110
  6. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncol. 2020 04 01; 6(4):505-511.
    View in: PubMed
    Score: 0.094
  7. A clinical perspective on regional nodal irradiation for breast cancer. Breast. 2017 Aug; 34 Suppl 1:S85-S90.
    View in: PubMed
    Score: 0.078
  8. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol. 2016 Apr; 2(4):508-16.
    View in: PubMed
    Score: 0.071
  9. Sonography and Sonographically Guided Needle Biopsy of Internal Mammary Nodes in Staging of Patients With Breast Cancer. AJR Am J Roentgenol. 2015 Oct; 205(4):905-11.
    View in: PubMed
    Score: 0.069
  10. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8.
    View in: PubMed
    Score: 0.062
  11. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol. 2012 Dec; 23(12):3063-3069.
    View in: PubMed
    Score: 0.055
  12. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2628-34.
    View in: PubMed
    Score: 0.051
  13. Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst. 2011 May 18; 103(10):798-809.
    View in: PubMed
    Score: 0.051
  14. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010 Sep 01; 116(17):4000-6.
    View in: PubMed
    Score: 0.048
  15. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer. 2009 Apr 15; 115(8):1605-12.
    View in: PubMed
    Score: 0.044
  16. Effects of variable placement of superior tangential/supraclavicular match line on dosimetric coverage of level III axilla/axillary apex in patients treated with breast and supraclavicular radiotherapy. Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):370-4.
    View in: PubMed
    Score: 0.043
  17. Identifying the "sentinel lymph nodes" for arm drainage as a strategy for minimizing the lymphedema risk after breast cancer therapy. Breast Cancer Res Treat. 2009 Aug; 116(3):539-41.
    View in: PubMed
    Score: 0.043
  18. Coexpression of alpha6beta4 integrin and guanine nucleotide exchange factor Net1 identifies node-positive breast cancer patients at high risk for distant metastasis. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):80-6.
    View in: PubMed
    Score: 0.043
  19. Breast cancer regional radiation fields for supraclavicular and axillary lymph node treatment: is a posterior axillary boost field technique optimal? Int J Radiat Oncol Biol Phys. 2009 May 01; 74(1):86-91.
    View in: PubMed
    Score: 0.042
  20. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008 Oct 01; 72(2):474-84.
    View in: PubMed
    Score: 0.041
  21. Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1022-7.
    View in: PubMed
    Score: 0.040
  22. Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1478-83.
    View in: PubMed
    Score: 0.039
  23. The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 2007 May 01; 68(1):59-65.
    View in: PubMed
    Score: 0.038
  24. Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):490-6.
    View in: PubMed
    Score: 0.038
  25. Accelerated partial breast irradiation. Curr Probl Cancer. 2007 Jan-Feb; 31(1):7-25.
    View in: PubMed
    Score: 0.038
  26. Optimizing locoregional control and survival for women with breast cancer: a review of current developments in postmastectomy radiotherapy. Expert Rev Anticancer Ther. 2006 Feb; 6(2):205-16.
    View in: PubMed
    Score: 0.035
  27. Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Dec 01; 63(5):1508-13.
    View in: PubMed
    Score: 0.034
  28. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jun 01; 62(2):351-7.
    View in: PubMed
    Score: 0.034
  29. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Apr 15; 103(8):1581-6.
    View in: PubMed
    Score: 0.033
  30. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1337-42.
    View in: PubMed
    Score: 0.032
  31. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004 Jun 15; 22(12):2303-12.
    View in: PubMed
    Score: 0.031
  32. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):138-45.
    View in: PubMed
    Score: 0.031
  33. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):336-44.
    View in: PubMed
    Score: 0.030
  34. Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: implications for post-mastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):128-35.
    View in: PubMed
    Score: 0.030
  35. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1225-33.
    View in: PubMed
    Score: 0.028
  36. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001 Jun; 8(5):425-31.
    View in: PubMed
    Score: 0.025
  37. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol. 2001 Apr 15; 19(8):2240-6.
    View in: PubMed
    Score: 0.025
  38. Internal mammary lymph nodes: to treat or not to treat. Int J Radiat Oncol Biol Phys. 2000 Mar 01; 46(4):801-3.
    View in: PubMed
    Score: 0.023
  39. Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am. 1999 May-Jun; 5(3):159-64.
    View in: PubMed
    Score: 0.022
  40. Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement. Int J Radiat Oncol Biol Phys. 2019 07 01; 104(3):574-581.
    View in: PubMed
    Score: 0.022
  41. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells. Breast Cancer Res. 2016 09 29; 18(1):97.
    View in: PubMed
    Score: 0.018
  42. Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):102-10.
    View in: PubMed
    Score: 0.017
  43. Metastatic Tumor Volume and Extranodal Tumor Extension: Clinical Significance in Patients With Stage II Breast Cancer. Arch Pathol Lab Med. 2015 Oct; 139(10):1288-94.
    View in: PubMed
    Score: 0.017
  44. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol. 2014 Nov 10; 32(32):3600-6.
    View in: PubMed
    Score: 0.016
  45. Determinants of practice patterns and quality gaps in lung cancer staging and diagnosis. Chest. 2014 May; 145(5):1097-1113.
    View in: PubMed
    Score: 0.016
  46. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 09; 310(14):1455-61.
    View in: PubMed
    Score: 0.015
  47. Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol. 2013 Oct; 20(11):3430-7.
    View in: PubMed
    Score: 0.015
  48. Evaluating locoregional recurrence in breast cancer. Int J Radiat Oncol Biol Phys. 2003 Mar 01; 55(3):850-1; author reply 851.
    View in: PubMed
    Score: 0.014
  49. Effectiveness of radiation for prevention of mastectomy in older breast cancer patients treated with conservative surgery. Cancer. 2012 Oct 01; 118(19):4642-51.
    View in: PubMed
    Score: 0.014
  50. The role of fast neutron radiation therapy in the management of advanced salivary gland malignant neoplasms. Cancer. 1992 Jun 01; 69(11):2779-88.
    View in: PubMed
    Score: 0.014
  51. Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer. 2012 Dec 15; 118(24):6287-96.
    View in: PubMed
    Score: 0.014
  52. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res. 2012 May 23; 14(3):R82.
    View in: PubMed
    Score: 0.014
  53. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer. 2012 Oct 01; 118(19):4652-9.
    View in: PubMed
    Score: 0.013
  54. Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant? Acad Radiol. 2012 May; 19(5):535-41.
    View in: PubMed
    Score: 0.013
  55. Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer. 2012 Mar 15; 118(6):1507-14.
    View in: PubMed
    Score: 0.013
  56. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012 Mar; 19(3):901-7.
    View in: PubMed
    Score: 0.013
  57. Impact of evidence-based clinical guidelines on the adoption of postmastectomy radiation in older women. Cancer. 2011 Oct 15; 117(20):4595-605.
    View in: PubMed
    Score: 0.013
  58. Long-term outcomes in patients with isolated supraclavicular nodal recurrence after mastectomy and doxorubicin-based chemotherapy for breast cancer. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1453-7.
    View in: PubMed
    Score: 0.012
  59. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010 Nov; 17(11):2899-908.
    View in: PubMed
    Score: 0.012
  60. Clinically apparent internal mammary nodal metastasis in patients with advanced breast cancer: incidence and local control. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1113-9.
    View in: PubMed
    Score: 0.011
  61. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 01; 27(34):5700-6.
    View in: PubMed
    Score: 0.011
  62. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol. 2009 Jan 10; 27(2):220-6.
    View in: PubMed
    Score: 0.011
  63. Risk of subclinical micrometastatic disease in the supraclavicular nodal bed according to the anatomic distribution in patients with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2008 Jun 01; 71(2):435-40.
    View in: PubMed
    Score: 0.010
  64. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007 Aug 15; 110(4):723-30.
    View in: PubMed
    Score: 0.010
  65. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005 Oct 01; 23(28):7098-104.
    View in: PubMed
    Score: 0.009
  66. Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer. 2005 Apr 01; 103(7):1323-9.
    View in: PubMed
    Score: 0.008
  67. Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol. 2003 Jul; 10(6):628-34.
    View in: PubMed
    Score: 0.007
  68. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol. 2000 Oct; 7(9):656-64.
    View in: PubMed
    Score: 0.006
  69. Presentation, management and outcome of axillary recurrence from breast cancer. Am J Surg. 2000 Oct; 180(4):252-6.
    View in: PubMed
    Score: 0.006
  70. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000 Aug; 18(15):2817-27.
    View in: PubMed
    Score: 0.006
  71. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol. 2000 Jul; 7(6):435-40.
    View in: PubMed
    Score: 0.006
  72. Frequency of first metastatic events in breast cancer: implications for sequencing of systemic and local-regional treatment. J Clin Oncol. 1999 Sep; 17(9):2649-58.
    View in: PubMed
    Score: 0.006
  73. Local-regional control of recurrent breast carcinoma after mastectomy: does hyperfractionated accelerated radiotherapy improve local control? Int J Radiat Oncol Biol Phys. 1999 Apr 01; 44(1):105-12.
    View in: PubMed
    Score: 0.005
  74. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999 Feb; 17(2):460-9.
    View in: PubMed
    Score: 0.005
  75. Feasibility of breast conservation therapy in metachronous or synchronous bilateral breast cancer. Ann Surg Oncol. 1999 Jan-Feb; 6(1):102-8.
    View in: PubMed
    Score: 0.005
  76. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998 Dec; 176(6):502-9.
    View in: PubMed
    Score: 0.005
  77. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am. 1998 Jul-Aug; 4(4):230-6.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.